Asherman’s Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Asherman's Syndrome Market Outlook

Thelansis’s “Asherman's Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Asherman's Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Asherman's Syndrome Overview

Asherman's syndrome, also known as intrauterine adhesions, arises due to trauma to the basal layer of the endometrium, typically occurring after the curettage of the endometrium following a recent pregnancy. These adhesions can range from minor to severe and impact both menstrual function and fertility. Asherman's syndrome primarily manifests after dilation and curettage procedures performed for elective termination of pregnancy, missed or incomplete miscarriage, or to treat a retained placenta after delivery. It may occur with or without hemorrhage following delivery or elective termination of pregnancy. In less frequent cases, it may develop after dilation and curettage for non-obstetrical reasons such as excessive bleeding, endometrial cancer sampling, or removal of endometrial polyps. Additionally, it can arise following surgical removal of uterine fibroids. The syndrome occurs when trauma or removal of the basal layer of the endometrium in opposing areas within the uterine cavity occurs. This injury triggers an inflammatory response that leads to adhesive bands forming from one side of the cavity to the other. Notably, abnormalities in placentation, where the placental tissue extends below the basal layer of the endometrium, significantly increase the risk of developing Asherman's syndrome. The extent of the adhesions determines the severity of the condition, categorized as mild, moderate, or severe. These adhesions can be thin or thick, located sporadically or in a confluent manner. It is important to note that the adhesive bands are typically avascular, which is crucial when discussing treatment options. The American Fertility Society classifies the severity of Asherman's syndrome into three stages: 1. Mild disease: characterized by a few filmy adhesions affecting less than one-third of the uterine cavity, with normal menstrual cycles or hypomenorrhea. 2. Moderate disease: marked by filmy and dense adhesions involving one-third to two-thirds of the cavity, resulting in hypomenorrhea. 3. Severe disease: characterized by dense adhesions affecting more than two-thirds of the cavity, leading to amenorrhea. Patients with moderate to severe disease have lower chances of conceiving and delivering a healthy pregnancy. However, surgical intervention may improve fertility outcomes if the uterine cavity can be reconstructed and menstrual cycles resume. It is important to note that even after repeated surgeries, restoring a normal endometrial lining may be delayed or not occur at all.

• Asherman's syndrome can occur in 31% of women after the initial hysteroscopic resection of leiomyoma (uterine fibroids), and the incidence can increase up to 46% after a second hysteroscopic resection.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: